Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page , B6 ~6 ~4 \4 P, m4 ~) U2 z, S! i
* R8 M' H" B% o c3 v
% r! N. C" X5 \, Q9 ASub-category:- d& \1 o: l- @! T' ~5 r
Molecular Targets 0 F9 @% J0 x& r, }, q" t7 k
4 ?4 M$ A; ^# c
. V: L( e3 I2 o; ~Category:9 g6 f7 J' B. z5 i) t
Tumor Biology
" ?6 D0 m$ e8 z: K5 |0 Q4 y4 Z6 u I$ B5 p6 Z
" x+ l; r( M/ A* c1 F1 U# ?
Meeting:
( j2 R+ g! c4 _" _3 p/ P2011 ASCO Annual Meeting
- b+ x. Y% a* ]5 v
* t( r" c* B G8 |, ]* }0 t" \, I8 p% o, |) v3 y
Session Type and Session Title:: i; b" J6 g1 ]3 w
Poster Discussion Session, Tumor Biology
8 Q7 @# i7 @) `: v! n5 q4 x' d4 Q/ k! c- {7 h% r6 n2 W
p6 g5 v. P% y; ~ S
Abstract No:
. Z) P/ G3 m2 o, n; ~. _1 u6 r10517 7 i% a1 C0 q7 d
" n6 F2 n, A8 _- u: V
+ }% X* v0 B4 v. |- t' v. y8 h {
Citation:2 R- A7 q/ g2 v' W+ w% d7 V5 l
J Clin Oncol 29: 2011 (suppl; abstr 10517)
4 A: w3 _) d6 z9 t
) T! Y' J! a) q! ]! Y& T" G1 q3 [: y M4 v+ q
Author(s):) P- G& e5 f' R
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
# [0 g+ R" [6 e, ~% j8 C
1 b! P, w/ ~. n% q
; P/ U$ s9 O1 E
E* R; e$ w( l0 _9 D* fAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.- C, m- G `3 }0 M6 A
* e7 U# M8 w8 f- K, t8 R# @( ]% sAbstract Disclosures7 Y! }0 t C0 D" [+ n
1 G& ?2 y4 y. t- ^: L9 o; z
Abstract:! A$ T, p7 ^9 g" u9 H; ]
3 z% q; ?5 a* d# J* L4 l8 [3 h9 P6 Z) Z3 z$ r4 i, v+ q- ]
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.4 |$ k, j7 r" h5 s8 p9 t+ Z
- L$ B1 a8 B8 O* s/ v7 N. W0 Q3 ` " u) c. o: V% B% `
|
破局疑难病例：间质性肺炎风险、脑膜
整理：雨过天晴审核：张蕻梅、钱哲、鹰版在应对肺癌这一复杂疾病时，多学科综合诊疗
肺腺癌术后不到两个月快速进展，求教
25年9月底，手术切除了右上肺，有两个淋巴转移，分期是2期。后续在进行辅助治疗的时候
流感高峰期，肿瘤患者要注意！抗病毒
作者：seacat
“我以为就是感冒，结果三天后高烧不退，还喘不上气。”
这是王阿姨（化
不知不觉进入第七年。。胸腔积液怎么
中间这几年很顺利也很稳定 这几年都没再关注这个平台。空窗一年半，最近一次复查胸腔
75岁老人肺癌有转移情况，是选择积极
还没有做 穿刺和基因检测，家里做医生的亲戚建议我姑息治疗，怕我人财2空
毕竟有75岁
显身卡
